Pharma BD Deal Intelligence
GSK pays Chinese-innovation prices for RNAi optionality: $40M upfront against $963M in milestones for two siRNA kidney-disease candidates, one still preclinical, with Frontier retaining Phase 1 work in China before GSK takes over global development.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK inks $1B-plus siRNA licensing pact with China-based Frontier Biotech for two early-stage kidney disease programs. The deal's structure — modest upfront,…
GSK backs siRNA modality through $1bn Frontier deal. The agreement gives GSK exclusive global rights outside China-origin development, with Frontier retaining…
Law firm advisory confirming GSK/Frontier exclusive worldwide siRNA license structure; describes agreement as prospective (will exclusively license), no close…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK entered a global exclusive licensing agreement with Shanghai Stock Exchange-listed Frontier Biotechnologies for two early-stage siRNA therapeutic candidates targeting inflammation-driven kidney diseases. GSK pays $40 million upfront with up to $963 million in development, regulatory, and commercial milestones, plus tiered royalties on global sales. Frontier advances the assets through Phase 1 in China and completes IND-enabling work; GSK assumes subsequent global clinical development, regulatory submissions, and commercialization. The deal extends GSK's siRNA pipeline following its earlier $745M Empirico COPD siRNA pact.
35.5M US cases/yr · $14.0B Global CKD drug market 2023 (analyst estimate, third-party)
Chronic kidney disease (CKD) driven by inflammation is a heterogeneous category encompassing IgA nephropathy, lupus nephritis, membranous nephropathy, focal segmental glomerulosclerosis, and diabetic kidney disease with inflammatory components. Per CDC, CKD affects an estimated 35.5 million US adults (1 in 7), and progression to end-stage renal disease remains a major driver of morbidity, mortality, and healthcare cost. The kidney is a favorable organ for siRNA delivery given hepatic GalNAc conjugation clears the liver and systemic RNAi can reach renal targets, and the liver-to-kidney axis (complement, APOL1, angiotensinogen) offers multiple validated inflammation-driven CKD targets. Existing IgA nephropathy and CKD approvals (Tarpeyo/budesonide, Filspari/sparsentan, Leqvio/inclisiran for LDL-C) leave substantial unmet need for durable, disease-modifying, target-specific inflammation blockade.
The inflammation-driven CKD siRNA competitive landscape is led by Alnylam Pharmaceuticals, with cemdisiran (C5 complement siRNA, Phase 2/3 in IgA nephropathy and lupus nephritis via Regeneron partnership) and zilebesiran (angiotensinogen siRNA, Phase 2 in hypertension with CKD implications). Novartis' Leqvio (inclisiran), a PCSK9 siRNA, anchors the broader liver-targeted RNAi category and validates the chronic dosing paradigm. In IgA nephropathy specifically, marketed disease-modifying agents include Calliditas/Everest Medicines' Tarpeyo/Kinpeygo (budesonide DR, oral) and Travere Therapeutics' Filspari (sparsentan, dual endothelin/angiotensin II blocker). Vera Therapeutics' atacicept (APRIL/BAFF inhibitor) is in Phase 3 for IgAN. Earlier-stage RNAi plays include Arrowhead's ARO-C3 and Dicerna/Novo Nordisk's discontinued nedosiran-related complement programs. GSK's two Frontier assets enter this landscape at IND-enabling/preclinical stage, positioning GSK to compete with Alnylam/Regeneron on next-generation kidney RNAi, following GSK's earlier $745M Empirico COPD siRNA deal in the same RNAi buildout.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Frontier Biotechnologies Inc. (this deal) | 2026 | $1.0B | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2026 deals · GlaxoSmithKline plc deals · Immunology deals